Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $41.83

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $42.00.

A number of research firms have commented on STOK. BTIG Research reaffirmed a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Weiss Ratings lowered Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wall Street Zen cut Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. The Goldman Sachs Group began coverage on Stoke Therapeutics in a report on Monday. They issued a “buy” rating and a $44.00 price objective for the company. Finally, Canaccord Genuity Group increased their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, March 20th.

Insider Activity

In other news, insider Barry Ticho sold 1,795 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $30.58, for a total value of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares of the company’s stock, valued at $1,064,979.08. This represents a 4.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares in the company, valued at $541,675.70. The trade was a 7.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in STOK. Kestra Advisory Services LLC bought a new position in Stoke Therapeutics during the fourth quarter worth about $26,000. KBC Group NV bought a new stake in shares of Stoke Therapeutics in the first quarter worth about $36,000. Harbour Investments Inc. increased its holdings in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in shares of Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period.

Stoke Therapeutics Stock Down 2.7%

Shares of STOK stock opened at $29.11 on Friday. The stock has a 50-day moving average price of $30.76 and a 200 day moving average price of $32.27. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -10.36 and a beta of 1.17. Stoke Therapeutics has a 12 month low of $11.89 and a 12 month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The company had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. Sell-side analysts predict that Stoke Therapeutics will post -3.22 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.